The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma

• Published in: Human pathology 2014-12, Vol.45 (12), p.2411-2416
• Main Authors: Steffens, Sandra, MD, Janssen, Martin, MD, Roos, Frederik C., MD, Becker, Frank, MD, Steinestel, Julie, MD, Abbas, Mahmoud, MD, Steinestel, Konrad, MD, PhD, Wegener, Gerd, MD, Siemer, Stefan, MD, Thüroff, Joachim W., MD, Hofmann, Rainer, MD, Stöckle, Michael, MD, Schrader, Mark, MD, Hartmann, Arndt, MD, Hasenfus, Andrea, MD, Kuczyk, Markus A., MD, Junker, Kerstin, MD, Schrader, Andres J., MD
• Format: Article
• Language: English
• Subjects: Age; Carcinoma, Renal Cell - mortality; Carcinoma, Renal Cell - pathology; Carcinoma, Renal Cell - surgery; Chromophobe RCC; Confidence intervals; Female; Fuhrman nuclear grading system; Histology; Humans; Kidney Neoplasms - mortality; Kidney Neoplasms - pathology; Kidney Neoplasms - surgery; Lymphatic Metastasis - pathology; Male; Medical prognosis; Metastasis; Middle Aged; Multivariate analysis; Neoplasm Grading; Pathology; Patients; Prognosis; Renal cell carcinoma; Retrospective Studies; Statistical methods; Studies; Survival; Survival Rate; Tumors
• ISSN: 0046-8177; 1532-8392
• DOI: 10.1016/j.humpath.2014.08.002

Summary The prognostic value of the Fuhrman nuclear grading system has been questioned for chromophobe renal cell carcinoma (chRCC) because this subtype frequently displays nuclear and nucleolar pleomorphism. The present study reevaluates this grading system in a series of patients with nonsarcomatoid chRCC. We identified 176 patients (3.6%) with nonsarcomatoid chRCC in a total of 4897 patients who underwent surgery for renal cell carcinoma at 5 centers in Germany between 1990 and 2010. The mean follow-up was 51.1 months. The 3 groups (G1 versus G2 versus G3/4) were comparable in terms of age, sex, tumor diameter, and lymph node metastasis. They only differed significantly in tumor stage ( P = .01) and the incidence of synchronous visceral metastasis ( P = .04). The 5-year cancer-specific survival rates were 84.4% for G1 (n = 32), 84.3% for G2 (n = 108), and 74.1% for G3/4 tumors (n = 33) ( P = .58). Accordingly, multivariate analysis including age, sex, tumor stage, and metastatic disease did not identify Fuhrman grading as an independent predictor of cancer-specific survival in patients with chRCC ( P = .4). We were able to demonstrate in a large multicenter cohort that the Fuhrman grading system does not qualify as a prognostic tool in patients with chRCC.